» Articles » PMID: 24465585

Atoxic Derivative of Botulinum Neurotoxin A As a Prototype Molecular Vehicle for Targeted Delivery to the Neuronal Cytoplasm

Overview
Journal PLoS One
Date 2014 Jan 28
PMID 24465585
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously described genetic constructs and expression systems that enable facile production of recombinant derivatives of botulinum neurotoxins (BoNTs) that retain the structural and trafficking properties of wt BoNTs. In this report we describe the properties of one such derivative, BoNT/A ad, which was rendered atoxic by introducing two amino acid mutations to the light chain (LC) of wt BoNT/A, and which is being developed as a molecular vehicle for delivering drugs to the neuronal cytoplasm. The neuronal binding, internalization, and intracellular trafficking of BoNT/A ad in primary hippocampal cultures was evaluated using three complimentary techniques: flow cytometry, immunohistochemistry, and Western blotting. Neuronal binding of BoNT ad was significantly increased when neurons were incubated in depolarizing medium. Flow cytometry demonstrated that BoNT/A ad internalized into neurons but not glia. After 24 hours, the majority of the neuron-bound BoNT/A ad became internalized, as determined by its resistance to pronase E-induced proteolytic degradation of proteins associated with the plasma membrane of intact cells. Significant amounts of the atoxic LC accumulated in a Triton X-100-extractable fraction of the neurons, and persisted as such for at least 11 days with no evidence of degradation. Immunocytochemical analysis demonstrated that the LC of BoNT/A ad was translocated to the neuronal cytoplasm after uptake and was specifically targeted to SNARE proteins. The atoxic LC consistently co-localized with synaptic markers SNAP-25 and VAMP-2, but was rarely co-localized with markers for early or late endosomes. These data demonstrate that BoNT/A ad mimics the trafficking properties of wt BoNT/A, confirming that our platform for designing and expressing BoNT derivatives provides an accessible system for elucidating the molecular details of BoNT trafficking, and can potentially be used to address multiple medical and biodefense needs.

Citing Articles

Pathogenicity and virulence of .

Rawson A, Dempster A, Humphreys C, Minton N Virulence. 2023; 14(1):2205251.

PMID: 37157163 PMC: 10171130. DOI: 10.1080/21505594.2023.2205251.


Neurotrophic effects of Botulinum neurotoxin type A in hippocampal neurons involve activation of Rac1 by the non-catalytic heavy chain (HC/A).

Solabre Valois L, Shi V, Bishop P, Zhu B, Nakamura Y, Wilkinson K IBRO Neurosci Rep. 2021; 10:196-207.

PMID: 34041508 PMC: 8143998. DOI: 10.1016/j.ibneur.2021.04.002.


A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Schwartz A, Ben David A, Hotoveli M, Dor E, Diamant E, Vivyorka A Antimicrob Agents Chemother. 2021; 65(8):e0042121.

PMID: 33972251 PMC: 8284437. DOI: 10.1128/AAC.00421-21.


Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.

McNutt P, Vazquez-Cintron E, Tenezaca L, Ondeck C, Kelly K, Mangkhalakhili M Sci Transl Med. 2021; 13(575).

PMID: 33408188 PMC: 8176400. DOI: 10.1126/scitranslmed.abd7789.


Novel Native and Engineered Botulinum Neurotoxins.

Steward L, Brin M, Brideau-Andersen A Handb Exp Pharmacol. 2020; 263:63-89.

PMID: 32274579 DOI: 10.1007/164_2020_351.


References
1.
Pellett S, Tepp W, Stanker L, Band P, Johnson E, Ichtchenko K . Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochem Biophys Res Commun. 2011; 405(4):673-7. PMC: 3046291. DOI: 10.1016/j.bbrc.2011.01.093. View

2.
Johnson E, Tepp W, Bradshaw M, Gilbert R, Cook P, McIntosh E . Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J Clin Microbiol. 2005; 43(6):2602-7. PMC: 1151885. DOI: 10.1128/JCM.43.6.2602-2607.2005. View

3.
Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, Bigalke H . Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem. 2004; 91(6):1461-72. DOI: 10.1111/j.1471-4159.2004.02844.x. View

4.
Stanker L, Merrill P, Scotcher M, Cheng L . Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. J Immunol Methods. 2008; 336(1):1-8. DOI: 10.1016/j.jim.2008.03.003. View

5.
Goodnough M, Oyler G, Fishman P, Johnson E, Neale E, Keller J . Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. 2002; 513(2-3):163-8. DOI: 10.1016/s0014-5793(02)02268-8. View